Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
Public ClinicalTrials.gov record NCT00283751. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes
Study identification
- NCT ID
- NCT00283751
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 583 participants
Conditions and interventions
Conditions
Interventions
- insulin detemir Drug
- insulin glargine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2003
- Primary completion
- Oct 31, 2004
- Completion
- Oct 31, 2004
- Last update posted
- Jan 26, 2017
2003 – 2004
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Greenbrae | California | 94904 | — |
| Novo Nordisk Investigational Site | La Mesa | California | 91942 | — |
| Novo Nordisk Investigational Site | West Palm Beach | Florida | 33401 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30318 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60607 | — |
| Novo Nordisk Investigational Site | Springfield | Illinois | 62711 | — |
| Novo Nordisk Investigational Site | Topeka | Kansas | 66606 | — |
| Novo Nordisk Investigational Site | Chesterfield | Missouri | 63017 | — |
| Novo Nordisk Investigational Site | St Louis | Missouri | 63141 | — |
| Novo Nordisk Investigational Site | Lincoln | Nebraska | 68521 | — |
| Novo Nordisk Investigational Site | Pleasantville | New Jersey | 08232 | — |
| Novo Nordisk Investigational Site | Cleveland | Ohio | 44195 | — |
| Novo Nordisk Investigational Site | Kettering | Ohio | 45429 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| Novo Nordisk Investigational Site | Mt. Pleasant | South Carolina | 29464 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75246 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75390-8858 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78229 | — |
| Novo Nordisk Investigational Site | Warrenton | Virginia | 20186 | — |
| Novo Nordisk Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00283751, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2017 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00283751 live on ClinicalTrials.gov.